Dyne Therapeutics Inc. (DYN)
11.46
-0.34 (-2.88%)
At close: Mar 28, 2025, 3:59 PM
11.45
-0.04%
After-hours: Mar 28, 2025, 04:33 PM EDT
-2.88% (1D)
| Bid | 10.72 |
| Market Cap | 1.3B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -352.09M |
| EPS (ttm) | -3.53 |
| PE Ratio (ttm) | -3.25 |
| Forward PE | -3.75 |
| Analyst | Buy |
| Ask | 12.49 |
| Volume | 691,796 |
| Avg. Volume (20D) | 2,118,693 |
| Open | 11.80 |
| Previous Close | 11.80 |
| Day's Range | 11.24 - 11.99 |
| 52-Week Range | 10.72 - 47.45 |
| Beta | 1.11 |
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therape...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 17, 2020
Employees 191
Stock Exchange NASDAQ
Ticker Symbol DYN
Website https://www.dyne-tx.com
Analyst Forecast
According to 12 analyst ratings, the average rating for DYN stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 336.49% from the latest price.
Stock Forecasts2 months ago
-2.98%
Dyne Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
2 months ago
-3.35%
Dyne Therapeutics shares are trading higher after the company announced it will release new clinical data from its Phase 1/2 ACHIEVE trial.
